Can patients with type 2 diabetes be treated with 5'-AMP-activated protein kinase activators?
Winder
W W
WW
Department of Physiology and Developmental Biology, Brigham Young University, Provo, UT 84602, USA. william_winder@byu.edu
D055372:AMP-Activated Protein Kinases / Q000378:metabolism*; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000201:enzymology*; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D008954:Models, Biological; D012265:Ribonucleotides / Q000494:pharmacology / Q000627:therapeutic use
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D012265:Ribonucleotides; D000620:Aminoimidazole Carboxamide; D055372:AMP-Activated Protein Kinases; C031143:AICA ribonucleotide